Read more about the article Navigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb
Navigating Challenges in a Single-Dose Study of a Recombinant Humanized mAb to Evaluate Pharmacokinetic and Immunogenicity Endpoints.

Navigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb

Study Overview: Conducting clinical studies for monoclonal antibodies (MABs) involves meticulous planning and execution, especially for recombinant humanized mAbs administered via intravenous (i.v.) infusion. This Recombinant humanized mAb targets subdomain…

Continue ReadingNavigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb
Read more about the article Poster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.
WRIB Poster -Singlicate well assay for the analysis of Enoxaparin Pharmacodynamic Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study. - Poster presented at 18th WRIB

Poster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.

BLOG

Continue ReadingPoster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.